University of Virginia
Charlottesville, Virginia, 22908, United States
NCT Number: NCT00600873
R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.
Looking for future studies?
Notify Me30 year–80 year
All sexes
Interventional
Phase 1 / Phase 2
Charlottesville, Virginia, 22908, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
100 mg tid orally daily
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Bennett, James P., Jr., M.D., Ph.D.
Indiv
Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01925196
Amyotrophic Lateral Sclerosis, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05562960
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Taipei, Taiwan
View Trial DetailsNCT04259255
ALS, Amyotrophic Lateral Sclerosis
Phoenix, Arizona, United States
View Trial DetailsNCT05189106
Alzheimer Disease, Amyotrophic Lateral Sclerosis
Boston, Massachusetts, United States
View Trial Details